


8:00 am Pre-Registration
 8:00 am – 9:45 am EXHIBIT HALL OPEN

8:30 AM – 9:30 AM PRE-CONGRESS CME SYMPOSIUM:

SUPPORTED BY: AMARIN



THE EVOLVING THERAPEUTIC ROLE OF ICOSAPENT ETHYL- IPE IN ASCVD AND BEYOND

Chair: Yehuda Handelsman, MD

- 8:30 am Introduction - TGL & CVD Risk | Pre-CME Questions
- 8:40 am The Role of Icosapent Ethyl in Atherosclerosis CVD & Stroke
- 8:55 am Beyond Cardiovascular Disease: Potential Future Uses of Icosapent Ethyl
- 9:10 am **Panel Discussion and Q&A: Omega-3 Fatty Acid Reality and Myth**
Panel: Yehuda Handelsman, MD • Matthew J. Budoff, MD • Peter Toth, MD
Moderator: Yehuda Handelsman, MD
- 9:25 am – 9:30 am Concluding Remarks & Post CME Questions

Yehuda Handelsman, MD
 Matthew J. Budoff, MD
 Peter Toth, MD

9:40 am – 10:00 am Welcome & Introduction | Pre-CME Questions

SESSION 1 COVID-19

Chairs: Paul Jellinger, MD • George Grunberger, MD

- 10:00 am MRAs for Prevention or Treatment of COVID-19 Christopher Wilcox, MD, PhD
- 10:15 am Cardiac Involvement and Management Approaches in Covid-19 Biykem Bozkurt, MD, PhD
- 10:30 am SGLT2i in COVID-19: DARE-19 Mikhail N. Kosiborod, MD
- 10:45 am – 11:05 am Panel Discussion and Q&A

SESSION 2 CONTEMPORARY APPROACH TO ASCVD IN DM

Chairs: Laurence Sperling, MD • Vivian A. Fonseca, MD

- 11:05 am Navigating Cardiometabolic Risk: Current and Emerging Approaches in the Diagnosis and Treatment of NAFLD Christos Mantzoros, MD
- 11:20 am The Interaction of Optimal Medical Therapy and Revascularization Strategies in Patients with Diabetes and Coronary Artery Disease Michael E. Farkouh, MD
- 11:35 am Anti Coagulation Agents in the Prevention of ASCVD in DM Peter J. Grant, MD
- 11:50 am The Role of DM Meds in Stroke Prevention Silvio E. Inzucchi, MD
- 12:05 pm – 12:25 pm Panel Discussion and Q&A

12:25 pm – 1:20 pm LUNCH BREAK

12:30 pm – 1:15 pm PRODUCT THEATER Non-CME Industry Supported Session
 Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C
 Supported by: Esperion

Norman Lopor, MD



SESSION 3 JOINT SYMPOSIUM WITH CIRCULATION

Chair: Darren McGuire, MD

- 1:20 pm Introduction
- 1:25 pm Effect of SGLT2 inhibition on Atrial Fibrillation Stephen D. Wiviott, MD
- 1:40 pm Regulatory Guidance on Newer Anti-Hyperglycemic Agents Neha J. Pagidipati, MD
- 1:55 pm Body Composition and Risk of CVD in Diabetes Kershaw V. Patel, MD
- 2:10 pm Gestational Diabetes, Subsequent Glucose Tolerance and Coronary Artery Calcium in Women: The CARDIA Study Erica P. Gunderson, PhD
- 2:25 pm Finerenone and CV Outcomes in CKD and Type 2 Diabetes Rajiv Agarwal, MD
- 2:40 pm – 3:00 pm Panel Discussion and Q&A

SESSION 4 DM & CVD IN DIVERSE POPULATIONS

Chairs: Jane EB Reusch, MD • Norman Lepor, MD

- | | | |
|-------------------|--|---------------------|
| 3:00 pm | Cardiovascular Disease in South Asians | Martha Gulati, MD |
| 3:15 pm | CVD in African Americans with Diabetes | Sam Dagogo-Jack, MD |
| 3:30 pm – 3:40 pm | Panel Discussion and Q&A | |

3:40 pm – 4:10 pm REFRESHMENT BREAK

SESSION 5 IMAGING OF ATHEROSCLEROSIS

Chairs: Robert J. Chilton, MD • Erin D. Michos, MD

- | | | |
|--|---|-----------------------|
| 4:10 pm | The Role of CV Risk Assessment of Asymptomatic Patients with Diabetes | Matthew J. Budoff, MD |
| 4:25 pm | The Best Imaging to Identify Atherosclerosis in Women | Leslee J. Shaw, PhD |
| DEBATE: THE BEST MODALITY TO PREDICT CV | | |
| 4:40 pm | Biomarkers | Brendan Everett, MD |
| 4:55 pm | Imaging | Norman Lepor, MD |
| 5:10 pm – 5:30 pm | Panel Discussion and Q&A | |

5:30 pm -6:30 pm DAY 1 SUMMARY SESSION & POST-CME QUESTIONS

Yehuda Handelsman, MD • Mikhail Kosiborod, MD • Darren McGuire, MD • Erin D. Michos, MD • Vivian A. Fonseca, MD • George Grunberger, MD

6:30 pm – 7:30 pm WELCOME AND POSTER RECEPTION

Online (Virtual) Only
6:30 pm- 7:15 pm PRODUCT THEATER Non-CME Industry Supported Session

Supported by: Novartis

7:30 PM – 9:00 PM DINNER CME SYMPOSIUM:

SUPPORTED BY: BAYER



DIABETES KIDNEY DISEASE NEXT FRONTIER IN THERAPY

Chair: Yehuda Handelsman, MD • Mikhail Kosiborod, MD

- | | | |
|-------------------|--|-----------------------|
| 7:30 pm | Introduction & Pre-CME Questions | |
| 7:35 pm | Diabetic Kidney Disease Epidemiology, Pathophysiology and Current Treatment | George L. Bakris, MD |
| 7:55 pm | The New Class of Non Steroidal MRA (focus on Finerenone) | Bertram Pitt, MD |
| 8:15 pm | The Evolving Management of CKD and HF | Mikhail Kosiborod, MD |
| 8:35 pm | Panel Discussion and Q&A: Emerging Management of DM and CKD – Case-Based | |
| | Panel: Rajiv Agarwal, MD • George L. Bakris, MD • Mikhail Kosiborod, MD • Bertram Pitt, MD | |
| | Moderator: Yehuda Handelsman, MD | |
| 8:55 pm – 9:00 pm | Concluding Remarks & Post-CME Questions | |

7:00 am – 8:00 am EXHIBIT HALL OPEN | Continental Breakfast

7:00 am – 7:45 am

PRODUCT THEATER Non-CME Industry Supported Session

Jardiance® (empagliflozin) tablets: A Review of the Latest Data
Supported by: Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC

Johanna Contreras, MD



8:00 am – 8:10 am Pre-CME Questions

SESSION 6 OBESITY, DIABETES AND THE HEART

Chairs: Robert J. Chilton, DO • Richard Pratley, MD

- 8:10 am Systemic Manifestation of Obesity – Focus on the Heart and Kidney Elizabeth Selvin, PhD
- 8:25 am Pharmacologic Strategies in Obesity Effect on Metabolic & CV Risk Donna H. Ryan, MD
- 8:40 am Contemporary Diets in the Prevention of CVD Pam R. Taub, MD
- 8:55 am – 9:10 am Panel Discussion and Q&A

SESSION 7 GUIDELINES UPDATE

Chairs: Jane EB Reusch, MD • Matthew J. Budoff, MD

- 9:10 am AHA Consensus: Management of Stable Coronary Disease in People with Diabetes Suzanne V. Arnold, MD
- 9:25 am ESC Prevention Guidelines Kausik Ray, MD
- 9:40 am ADA Standard of Care Update Jennifer Green, MD
- 9:55 am – 10:15 am Panel Discussion and Q&A

10:15 am – 10:45 am REFRESHMENT BREAK AT EXHIBIT HALL

SESSION 8 RECENT DIABETES PUBLICATIONS IN CARDIOLOGY

Chair: Michael E. Farkouh, MD

- 10:45 am Introduction
- 10:50 am Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar Jeffrey I. Mechanick, MD
- 11:05 am Influence of LDL-C on Cardiovascular Outcomes in Patients With Diabetes Undergoing Coronary Revascularization Lucas Godoy, MD
- 11:20 am 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Melissa L. Magwire, RN,MSN, CDES
- 11:35 am Role of Biomarker in Heart Failure Risk Prediction in Individuals with Dysglycemia Ambarish Pandey, MD
- 11:50 am Q&A
- 12:05 pm – 12:20 pm Panel Discussion

12:20 pm – 1:30 pm LUNCH BREAK

12:30 pm – 1:20 pm

PRODUCT THEATER Non-CME Industry Supported Session

A Focus on Very High-Risk Patients in the Acute Setting: Understanding Plaque and Prioritizing LDL-C
Michael J. Blaha MD MPH
Supported by: Amgen

SESSION 9 ADVANCED TECHNOLOGIES & DIGITAL HEALTH

Chairs: Daniel Einhorn, MD • Martha Gulati, MD

- 1:30 pm CGM Impact on CVD – focus on TIR George Grunberger, MD
- 1:45 pm CGM Role in T2D on Lifestyle +/- Oral Medications Viral Shah, MD
- 2:00 pm Impact of Glucose Variability on CVD Richard E. Pratley, MD
- 2:15 pm – 2:30 pm Panel Discussion and Q&A

SATURDAY SEPTEMBER 11, 2021 (cont.)

2:30 pm **AWARD PRESENTATION “LUMINARY IN CARDIOMETABOLIC MEDICINE”**
2:35 pm Lipids, Obesity, Metabolic Syndrome, Diabetes and the Heart - My Professional Journey
3:05 pm – 3:15 pm Q&A

Robert H. Eckel, MD



3:15 pm – 3:45 pm REFRESHMENT BREAK AT EXHIBIT HALL

SESSION 10 CVOT

Chairs: Mikhail Kosiborod, MD • Matthew R. Weir, MD

3:45 pm Update on CVOT

Deepak L. Bhatt, MD

DEBATE: SHOULD BRAND NEW DATA BE RAPIDLY ADOPTED BY GUIDELINES?

4:15 pm Yes

Robert J. Chilton, DO

4:30 pm No

Sanjay Kaul, MD

4:45 pm – 5:05 pm Panel Discussion and Q&A

SESSION 11 SLEEP APNEA AND METABOLISM

Chairs: Christian W. Mende, MD • Neha Pagidipati, MD

5:05 pm OSA Hyperglycemia and Diabetes

Naresh Punjabi, MD

5:20 pm Sleep Apnea and Cardiovascular Disease: Evidence, Mechanism, and Treatment

Henry Klar Yaggi, MD

5:35 pm – 5:45 pm Panel Discussion and Q&A

5:45 pm – 6:45 pm **DAY 2 SUMMARY SESSION & POST-CME QUESTIONS**
Yehuda Handelsman, MD • Sanjay Kaul, MD • Richard E. Pratley, MD •
Jane EB Reusch, MD • Michael E. Farkouh, MD • Daniel Einhorn, MD

6:45 PM – 8:30 PM **DINNER CME SYMPOSIUM:**

SUPPORTED BY: ASTRAZENECA



KIDNEY DISEASE AND THE HEART IN DIABETES & BEYOND – CIRCA 2021

Chairs: Matthew Weir, MD • Yehuda Handelsman, MD

7:00 pm Introduction & Pre-CME Questions

7:05 pm CKD Impact on Health and Disease

Ian De Boer, MD

7:25 pm Contemporary Approach to Prevention Management of Heart Failure

TBD

7:45 pm Emerging Concepts in Management of CKD – the Prevention of Morbidity and Mortality

Robert D. Toto, MD

8:05 pm **Panel Discussion and Q&A:** Kidney and Heart Diseases – Causality Dilemma

Panel: Yehuda Handelsman, MD • Ian De Boer, MD • TBD • Robert D. Toto, MD

Moderator: Matthew Weir, MD

8:25 pm – 8:30 pm Concluding Remarks & Post-CME Questions

SUNDAY SEPTEMBER 12, 2021

7:00 am – 8:00 am **Registration | Continental Breakfast**

7:00 am – 8:00 am **ABSTRACT ORAL PRESENTATIONS**

Abstracts are published in the American Heart Journal, Editor-in-Chief: Daniel Mark, MD, MPH

Chair: George Grunberger, MD

Abstract Committee: Zachary T. Bloomgarden, MD • Matthew J. Budoff, MD • Vivian A. Fonseca, MD •

Norman E. Lepor, MD • Derek LeRoith, MD, PhD • Laurence Sperling, MD

Refreshments will be served

8:00 am – 8:10 am Pre-CME Questions

8:10 am – 8:15 am **Oral Abstract Winner Award Presentation**

George Grunberger, MD

SESSION 12 MANAGEMENT OF DIABETES CIRCA 2021

Chairs: Silvio E. Inzucchi, MD • Ralph A. DeFronzo, MD

8:15 am	100 Years of Insulin and the Heart	Vivian A. Fonseca, MD
8:30 am	Early and Intensive Management of Diabetes with SGLT2i & GLP1-ra	Stefano Del Prato, MD
8:45 am	The Metabolic Impact of Hypoglycemia & Contemporary Approach to Management	Daniel Einhorn, MD
9:00 am – 9:15 am	Panel Discussion and Q&A	

SESSION 13 HEART DISEASE IN WOMEN

Chairs: Martha Gulati, MD • Laurence Sperling, MD

9:15 am	CVD and PCOS – Smoke versus Fire	Andrea Dunaif, MD
9:30 am	Link Between Migraine & CVD Implications for Management	Gina P. Lundberg, MD
9:45 am	Sex Hormone Impact on Heart Failure in Men and Post-Menopausal Women	Erin D. Michos, MD
10:00 am – 10:20 am	Panel Discussion and Q&A	

10:20 am – 10:35 am REFRESHMENT BREAK AT EXHIBIT HALL**SESSION 14 DYSLIPIDEMIA AND ASCVD**

Chairs: Neha J. Pagidipati, MD • Paul Jellinger, MD

10:35 am	Role of New Agents in Managing Dyslipidemia of DM to Reduce CVD	Christie M. Ballantyne, MD
10:50 am	Management of Dyslipidemia in Young People with Diabetes	Elaine M. Urbina, MD
11:05 am	The Subclinical Progression of Arterial Disease Evaluated by US, MRI, & PET: Role of LDL-C and Other Risk Factors	Valentin Fuster, MD, PhD
11:20 am – 11:40 am	Panel Discussion and Q&A	

11:40 am – 12:35 pm LUNCH/CHECK OUT BREAK

11:45 am – 12:30 pm **PRODUCT THEATER Non-CME Industry Supported Session**
 Hidden Hypercortisolism: What Are We Missing and Why Does It Matter?
 Supported by: Corcept

Daniel Einhorn, MD

**SESSION 15 HF & CKD OR THE CARDIORENAL SYNDROME?**

Chairs: Darren McGuire, MD • Christian W. Mende, MD

12:35 pm	Kidney Disease in Diabetes: Implications for Therapy	Ralph A. DeFronzo, MD
12:50 pm	Contemporary Approach to Medications in CKD Control	Mark J. Sarnak, MD
1:05 pm	The Contemporary Role of Medications and the Heart	Laurence Sperling, MD
1:20 pm	2021 HFpEF vs. HFrEF	John McMurray, MD
1:35 pm	State-of-the-art Management of Hyperkalemia in HF & CKD	Matthew R. Weir, MD
1:50 pm	Management of HF – What Should the Guidelines Be?	Javed Butler, MD
2:05 pm – 2:30 pm	Panel Discussion: Cardiorenal Syndrome Is it More than the Individual Components	

2:30 pm – 3:30 pm **DAY 3 SUMMARY SESSION & POST-CME QUESTIONS**
 Yehuda Handelsman, MD • Darren McGuire, MD • Christian Mende, MD •
 Ralph A. DeFronzo, MD • Martha Gulati, MD • Laurence Sperling, MD

3:30 pm **ADJOURN**